目的  探究血清中性粒细胞明胶酶相关脂质运载蛋白(neutrophil gelatinase-associated lipocalin，NGAL)、降钙素原(procalcitonin，PCT)、白细胞介素-6(interleukin-6，IL-6)水平对维持性血液透析(maintenance hemodialysis，MHD)患者并发导管相关性感染(catheter-related infection，CRI)的联合预测价值。 方法  选择2022年8月─2025年8月南阳市中心医院进行MHD治疗的尿毒症患者150例，根据并发CRI情况分为感染组(32例)与非感染组(118例)，测定血清NGAL、PCT、IL-6水平，多因素Logistic分析MHD患者并发CRI的影响因素，受试者工作特征(receiver operating characteristic，ROC)曲线分析血清NGAL、PCT、IL-6水平对MHD患者并发CRI的预测价值。 结果  感染组糖尿病占比、置管时间、NGAL、PCT、IL-6水平高于非感染组(χ2/t=4.476、3.330、6.932、7.467、7.983，P=0.034、0.001、＜0.001、＜0.001、＜0.001)。NGAL、PCT、IL-6是尿毒症MHD患者并发CRI的危险因素(OR=2.064、2.716、2.192，95% CI：1.153～3.694、1.275～5.788、1.119～4.293，P=0.015、0.010、0.022)。血清NGAL、PCT、IL-6预测尿毒症MHD患者并发CRI的AUC分别为0.771(95%CI：0.680～0.862)、0.851(95%CI：0.777～0.925)、0.819(95%CI：0.724～0.913)，三者联合预测尿毒症MHD患者并发CRI的AUC为0.926(95%CI：0.867～0.985)，优于单独预测(Z三者联合比NGAL=3.864、P=0.001，Z三者联合比PCT=2.327、P=0.020，Z三者联合比IL-6=2.495、P=0.013)。 结论  NGAL、PCT、IL-6升高与尿毒症MHD患者并发CRI风险升高密切相关，三者联合对尿毒症MHD患者并发CRI具有一定预测价值。

Objective To investigate the combined predictive value of serum neutrophil gelatinase-associated lipocalin (NGAL), procalcitonin (PCT), and interleukin-6 (IL-6) levels for catheter-related infection (CRI) in uremic patients undergoing maintenance hemodialysis (MHD).  Methods A total of 150 uremic patients receiving MHD at Nanyang Central Hospital between August 2022 and August 2025 were enrolled in this study. Patients were divided into an infection group (n=32) and a non-infection group (n=118) based on the presence or absence of CRI. Serum levels of NGAL, PCT, and IL-6 were measured. Multivariate logistic regression analysis was used to identify factors influencing CRI in MHD patients. Receiver operating characteristic (ROC) curves were constructed to evaluate the predictive performance of serum NGAL, PCT, and IL-6 levels for CRI.  Result The proportion of diabetes mellitus, catheterization time, NGAL, PCT and IL-6 levels in the infection group were higher than those in the non-infection group (χ2/t=4.476, 3.330, 6.932, 7.467 and 7.983 respectively; P=0.034, 0.001, ＜0.001, ＜0.001 and ＜0.001 respectively). Serum NGAL, PCT and IL-6 were the risk factors for CRI in uremic MHD patients (OR=2.064, 2.716 and 2.192 respectively; 95% CI:1.153～3.694, 1.275～5.788 and 1.119～4.293 respectively; P=0.015, 0.010 and 0.022 respectively). The AUC of serum NGAL, PCT and IL-6 for predicting CRI in uremic MHD patients were 0.771 (95% CI:0.680～0.862), 0.851 (95% CI:0.777～0.925) and 0.819 (95% CI:0.724～0.913) respectively. The AUC of combined serum NGAL, PCT and IL-6 levels for predicting CRI in uremic MHD patients was 0.926 (95% CI:0.867～0.985), better than that of individual level for prediction (Z combined-NGAL=3.864, P=0.001; Z combined-PCT=2.327, P=0.020; Z combined-IL-6=2.495, P=0.013).  C onclusion  Elevated NGAL, PCT, and IL-6 levels are closely related to an increased risk of CRI in uremic MHD patients. The combined use of the three serum levels predicts CRI better in uremic MHD patients.